BioSpace

Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal

The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.

By BioSpace

1 min read
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights